ICOS and male reproductive organ cancer: Fan et al. concluded that the combination of CTLA-4 blockade and ICOS engagement by tumor cell vaccines, engineered to express ICOS ligand, qualitatively and quantitatively increased antitumor immune responses and considerably promoted the rejection of developed prostate and melanoma cancer in mice (Fan et al., 2014[19]).